Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel

Dasatinib is a potent oral tyrosine kinase inhibitor which targets several kinases, including the SRC family kinases. SRC family kinases have been implicated in androgen therapy resistance that often develops in metastatic castration-resistant prostate cancer (mCRPC), which drives the need for non-a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Araujo, John C, Trudel, Geralyn C, Paliwal, Prashni
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2013
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3601649/
https://ncbi.nlm.nih.gov/pubmed/23516140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S41667
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars